Sort
48,018 grants matching “immunotherapy”
Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection
$934,898Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2024 · AI
Crystallographic studies of macromolecular structures
$934,864Lars Pedersen · National Institute Of Environmental Health Sciences · ZIA · FY2009 · ES
Metabolic reprogramming of the tumor microenvironment and therapy resistance
$934,799Ernst Lengyel · University Of Chicago · R35 · FY2024 · CA
Immune function and the progression to type 1 diabetes
$934,682University Of Florida · P01 · FY2001 · AI
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
$934,422Samirkumar Patel · Moonlight Therapeutics, Inc. · R42 · FY2021 · AI
Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers
$934,220Christian Hinrichs · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Comparative Modeling for the Prevention and Control of Uterine Cancer
$933,993Jason Wright · Columbia University Health Sciences · U01 · FY2022 · CA
Defining Drivers of HPV-associated Carcinogenesis
$933,000Paul F Lambert · University Of Wisconsin-Madison · R35 · FY2024 · CA
NOVEL THERAPEUTIC STRATEGIES IN LEUKEMIA AND LYMPHOMA
$932,947Dana-Farber Cancer Institute · P01 · FY2001 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
$932,751Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2023 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
$932,751Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2024 · CA
A Yeast-based Immunotherapy against Clostridioides difficile infection
$932,749Zhiyong Yang · Fzata, Inc. · R44 · FY2022 · AI
VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
$932,733Vanderbilt University · U01 · FY2001 · AI
U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
$932,592University Of Texas Sw Med Ctr/Dallas · U01 · FY2001 · AI
Using gene expression profiles to elucidate mechanisms of melanoma progression
$932,378Ashani Weeraratna · Aging · Z01 · FY2007 · AG
MRI of tumor-infiltrating lymphocytes using MRI-cytometry
$932,260Junzhong Xu · Vanderbilt University Medical Center · R01 · FY2025 · CA
Next Generation Immunotherapies for Pediatric Cancers
$932,006Crystal Mackall · Stanford University · R35 · FY2025 · CA
Systems genetics analysis of tumor evolution in the mouse
$931,980Allan Balmain · University Of California, San Francisco · R35 · FY2022 · CA
Systems genetics analysis of tumor evolution in the mouse
$931,980Allan Balmain · University Of California, San Francisco · R35 · FY2023 · CA
Next Generation Immunotherapies for Pediatric Cancers
$931,841Crystal Mackall · Stanford University · R35 · FY2024 · CA
Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection
$931,829Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2025 · AI
Lipid mediated oral tolerance
$931,012Sathy Venkat Balu-Iyer · State University Of New York At Buffalo · R01 · FY2025 · AI
UNIVERSITY OF P.R., PEDIATRIC AIDS CLINICAL TRIALS UNIT
$930,940University Of Puerto Rico Med Sciences · U01 · FY2001 · AI
Defining Drivers of HPV-associated Carcinogenesis
$930,851Paul F Lambert · University Of Wisconsin-Madison · R35 · FY2025 · CA
Strategies for improving early detection, diagnosis and treatment of liver cancer
$930,599Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA